1. Introduction {#sec1-ijms-19-00693}
===============

Connexin 43 (Cx43), a protein encoded by the Gap Junction protein alpha 1 gene (*GJA1*), forms gap junction transmembrane channels facilitating communication between the cytoplasm of two adjacent cells. Small molecules, including metabolites, second messengers and electrical signals pass through these channels in a process called Gap Junction Intercellular Communication (GJIC). Cx43 transcription is thought to be regulated both by transcription factors and by epigenetic mechanisms \[[@B1-ijms-19-00693]\], but is also regulated at the protein level by post-transcriptional modifications, trafficking to and from the plasma membrane and gating of the channels \[[@B2-ijms-19-00693]\].

The breast epithelium is composed of two layers of cells: an inner layer of luminal cells surrounded by an outer layer of basal cells, composed mainly of myoepithelial cells but also comprising stem and progenitor cell populations \[[@B3-ijms-19-00693]\]. It is well established that Cx43 is expressed mainly in the basal layer; however, a few studies showed Cx43 expression in luminal cells \[[@B4-ijms-19-00693],[@B5-ijms-19-00693],[@B6-ijms-19-00693]\]. A study using transmission electron microscopy reported gap junctions to be present between the basal and the luminal layers in normal breast tissues, although the exact connexin involved was not determined \[[@B7-ijms-19-00693]\]. A few studies have also demonstrated the expression of Cx43 in fibroblasts surrounding the breast epithelium and in endothelial cells \[[@B8-ijms-19-00693],[@B9-ijms-19-00693],[@B10-ijms-19-00693]\].

The role of Cx43 in breast cancer is controversial. On the one hand, Cx43 has long been considered a tumor suppressor \[[@B11-ijms-19-00693]\] with studies demonstrating it was under-expressed at the mRNA and the protein level in cancer cell lines \[[@B12-ijms-19-00693],[@B13-ijms-19-00693]\] or aberrant localization and phosphorylation in tumors \[[@B12-ijms-19-00693],[@B13-ijms-19-00693],[@B14-ijms-19-00693],[@B15-ijms-19-00693],[@B16-ijms-19-00693]\]. Cx43 has also been linked to the control of processes associated with breast cancer progression and metastasis such as proliferation, invasion, migration and apoptosis \[[@B17-ijms-19-00693]\]. Moreover, it was shown in vivo and in vitro that metastatic capacity was increased in tumors cells showing a weak GJIC capacity and a lower number of gap junction plaques \[[@B18-ijms-19-00693],[@B19-ijms-19-00693]\]. Re-expression of Cx43 in tumor cells led to reduced growth of tumors in nude mice and fewer metastases to the lungs \[[@B20-ijms-19-00693],[@B21-ijms-19-00693]\]. Mice expressing a mutant form of Cx43 (G60S) also showed increased breast tumor metastasis to the lung \[[@B3-ijms-19-00693]\].

On the other hand, much evidence suggested that Cx43 is involved in later stages of breast cancer progression. For instance, it has been suggested that Cx43 mediates the interaction between tumor and endothelial cells to facilitate adhesion and extravasation at secondary sites \[[@B22-ijms-19-00693],[@B23-ijms-19-00693],[@B24-ijms-19-00693]\]. Cx43 has also been found to be expressed at higher levels in lymph node metastasis than in the corresponding primary tumor \[[@B25-ijms-19-00693]\]. The context of expression that allows Cx43 to act as a tumor suppressor or promoter has not been elucidated and therefore precludes its targeting in breast cancer therapies \[[@B11-ijms-19-00693]\].

Breast cancer is highly heterogeneous, with both intra- and inter-tumoral molecular variability. During the last decade, high throughput techniques have generated a body of new data in many diseases including breast cancer. Genome-wide gene expression profiling has produced classification schemes including the intrinsic subtypes consisting of luminal A (LumA), luminal B (LumB), basal-like and HER2-enriched (Her2e) tumors. Luminal tumors are generally characterized by the expression of the estrogen receptor alpha (ER$\alpha$) and the progesterone receptors (PR). Most Her2e tumors harbor a genomic amplification of chromosome 17q12 that contains the erb-b2 receptor tyrosine kinase 2 gene (ERBB2/HER2). Approximately half of Her2e tumors express ER$\alpha$. Basal-like tumors are often negative for ER$\alpha$ or PR receptors as well as for HER2 and also express basal cytokeratins \[[@B26-ijms-19-00693],[@B27-ijms-19-00693]\].

This study aims to investigate Cx43's ambiguous role during cancer progression with each of the breast tumor intrinsic subtypes using a compendium of publicly available gene expression data with large samples. Here, we report that Cx43 expression depends greatly on intrinsic subtype. Tumor grade also co-varies with patient subtype, resulting in Cx43 co-expression with grade in a subtype-dependent manner. Better survival was associated with a high expression of Cx43 in unstratified and luminal tumors but with a low expression in the Her2e subtype.

2. Results {#sec2-ijms-19-00693}
==========

2.1. *GJA1* Expression and Localization in the Breast {#sec2dot1-ijms-19-00693}
-----------------------------------------------------

We first investigated the tissue localization and level of expression of Cx43 protein in human samples of both morphologically normal breast tissue and tumors using the Human Protein Atlas. This is a public database containing a large collection of normal and cancer tissue slides which have been probed with various antibodies followed by a hematoxylin counterstain \[[@B28-ijms-19-00693]\]. Cx43 is a membrane channel and is usually considered to be expressed in the myoepithelial cell. A typical punctate staining of junctional plaques formed by Cx43 channels was observed for normal tissues. The staining could be observed in the myoepithelial layer, as expected, but also in some luminal cells ([Figure 1](#ijms-19-00693-f001){ref-type="fig"}a). Although an under-expression of Cx43 protein is observed in some of the 21 cancer samples available ([Figure 1](#ijms-19-00693-f001){ref-type="fig"}a), others show a clear over-expression, mostly in well differentiated luminal-like neoplastic cells, which did not appeared to be associated with a basal layer ([Figure 1](#ijms-19-00693-f001){ref-type="fig"}c). In other samples, Cx43 could also be seen in a layer of cells separating neoplastic tissue from stroma, although this layer sometimes adhered poorly to both adjacent compartments ([Figure 1](#ijms-19-00693-f001){ref-type="fig"}d,e). Cx43 was also observed in samples with poorly differentiated cell and tissue morphology ([Figure 1](#ijms-19-00693-f001){ref-type="fig"}f,g). Interestingly, Cx43 protein could also be found in spindle-shaped cells in the stroma ([Figure 1](#ijms-19-00693-f001){ref-type="fig"}h). Overall, some normal punctate patterns could be observed in some tumors ([Figure 1](#ijms-19-00693-f001){ref-type="fig"}d) while the majority of the samples showed either a downregulation or an aberrant cytoplasmic localization of Cx43 in tumor cells.

We next compared transcript levels of *GJA1* in breast tumor samples and in the non-cancerous adjacent tissues using microarray-based data of The Cancer Genome Atlas project (TCGA) breast invasive carcinoma cohort (BRCA) of clinical samples. We observed a far greater variance in mRNA expression in tumor samples compared to tumor adjacent morphologically normal breast tissue ([Figure 1](#ijms-19-00693-f001){ref-type="fig"}i, the Fligner--Killeen test of homogeneity of variances, *p* value \< 10^−12^). We also used whole sample Cx43 protein levels obtained for 105 TCGA samples by mass spectrometry. *GJA1* mRNA and protein level are significantly correlated ([Figure 1](#ijms-19-00693-f001){ref-type="fig"}j, (Pearson correlation rho = 0.6515, *p* value \< e^−13^). Our results confirm that, in breast cancer, *GJA1* is concurrently dysregulated at both the protein and the mRNA level.

2.2. *GJA1* Expression Varies with Breast Cancer Subtype {#sec2dot2-ijms-19-00693}
--------------------------------------------------------

We then speculated that *GJA1* variability could be linked to the molecular heterogeneity of breast cancer. When we compared *GJA1* mRNA expression after stratifying patient samples by their intrinsic subtype (Pam50 by genefu \[[@B29-ijms-19-00693]\]) ([Figure 2](#ijms-19-00693-f002){ref-type="fig"}a), the increase in variance in gene expression of tumor samples relative to normal tissue was observed in every subtype. The LumA had a mean expression level statistically indistinguishable from morphologically normal samples, but a small significant progressive decrease in expression is observed from LumB to basal and Her2e subtypes ([Figure 2](#ijms-19-00693-f002){ref-type="fig"}a).

A similar pattern was observed in the four other datasets, although normal breast tissues were only used in TCGA and Curtis datasets ([Figure A1](#ijms-19-00693-f0A1){ref-type="fig"}). A similar pattern was also observed at the protein level in the TCGA dataset ([Figure 2](#ijms-19-00693-f002){ref-type="fig"}b). Together, these results suggest that the expression of *GJA1* is strongly associated with tumor subtype and is more variable in each subtype in comparison to morphologically normal tissue.

2.3. Somatic DNA-Level Events of *GJA1* Do Not Drive Expression Changes of *GJA1* in Breast Cancer {#sec2dot3-ijms-19-00693}
--------------------------------------------------------------------------------------------------

We next asked if underlying DNA-level somatic copy number changes in the genomic loci harboring *GJA1* influence gene expression levels. For the TCGA dataset, a few tumors had amplification or deletion of *GJA1*, compared to genes known to be amplified in breast cancer ([Figure 3](#ijms-19-00693-f003){ref-type="fig"}a).

Moreover, tumors with *GJA1* amplification did not show an increase in expression while only deep deletions reduced expression (−2 in called copy number, as shown in [Figure 3](#ijms-19-00693-f003){ref-type="fig"}c). Most luminal tumors with the highest expression of *GJA1* were found to have either a normal copy number or single deletion ([Figure 3](#ijms-19-00693-f003){ref-type="fig"}b--d). Moreover, in tumors with a *GJA1* gain or amplification, a slight but significant decrease in expression, rather than an increase, could be observed compared to normal tissues ([Figure 3](#ijms-19-00693-f003){ref-type="fig"}c). *GJA1* mRNA also weakly negatively correlated with DNA copy number ([Figure 3](#ijms-19-00693-f003){ref-type="fig"}c), suggesting that Cx43 over-expression in breast cancer is not driven by DNA amplification. To validate our procedure, we used the *HSF2* gene, a close neighbor of *GJA1* on chr6q22 which shares similar copy number in 99% of TCGA's breast cancer cases. In contrast to what was observed for *GJA1*, *HSF2* mRNA was positively correlated with the copy number of its own gene ([Figure 3](#ijms-19-00693-f003){ref-type="fig"}c). Moreover, somatic point mutation data showed that, in the TCGA cohort, only three breast cancer patients out of 977 harbored at least one *GJA1* mutation, accounting for 0.31% of the tumors ([Figure 3](#ijms-19-00693-f003){ref-type="fig"}e). Only one tumor with an extremely high number of total mutations (TCGA-AN-A046) was found to have both a *GJA1* mutation and a slightly higher expression of the gene (2.76) compared to normal range (−1.01 to 2.20) ([Figure 3](#ijms-19-00693-f003){ref-type="fig"}c,e). Together, these results argue that loss or amplification of the *GJA1* gene likely does not dictate mRNA and protein dysregulation in breast cancer.

2.4. *GJA1* Level Is Dependent on Hormonal Receptor Status {#sec2dot4-ijms-19-00693}
----------------------------------------------------------

Because Cx43 level varies through the mammary gland development and the reproductive cycle, it has been suggested that it could be regulated by hormones, similar to what has been observed in other tissues \[[@B4-ijms-19-00693],[@B30-ijms-19-00693],[@B31-ijms-19-00693],[@B32-ijms-19-00693]\]. We thus next investigated whether the *GJA1* mRNA level was directly linked with hormonal receptors status.

Consistent with the subtype-specific expression of Cx43, ER$\alpha$- or PR-positive breast tumors had a significantly higher expression of *GJA1* mRNA compared to ER$\alpha$- or PR-negative tumors ([Figure 4](#ijms-19-00693-f004){ref-type="fig"}a, [Figure A1](#ijms-19-00693-f0A1){ref-type="fig"}, [Figure A2](#ijms-19-00693-f0A2){ref-type="fig"} and [Figure A3](#ijms-19-00693-f0A3){ref-type="fig"}). Results were similar for all five datasets, except for PR in the NKI dataset where the low number of samples did not allow statistical significance to be reached ([Figure 4](#ijms-19-00693-f004){ref-type="fig"}a, [Figure A2](#ijms-19-00693-f0A2){ref-type="fig"}a and [Figure A3](#ijms-19-00693-f0A3){ref-type="fig"}a). However, there were no strong correlations between *GJA1* expression and *ESR1* mRNA, with total protein level (ER$\alpha$), or with the activated form of ER$\alpha$ phosphorylated on serine 118 (ER$\alpha$\_pS118) ([Figure 4](#ijms-19-00693-f004){ref-type="fig"}b--e and [Figure A1](#ijms-19-00693-f0A1){ref-type="fig"}b,c). While only weak correlations were observed in most individual subtypes, a stronger correlation between *GJA1* and *ESR1* mRNA and protein was observed when the tumors were pooled ([Figure 4](#ijms-19-00693-f004){ref-type="fig"}b--d). As expected, *ESR1* mRNA was better correlated with total ER$\alpha$ (Pearson's rho = 0.9011, Spearman's rho = 0.8969) than with ER$\alpha$\_pS118 proteins (Pearson's rho = 0.5459, Spearman's rho = 0.6407).

Stronger correlations between *PGR* mRNA and protein levels and *GJA1* mRNA levels were observed, not only in unstratified (pooled) analysis, but also in individual subtypes within most datasets ([Figure 4](#ijms-19-00693-f004){ref-type="fig"}b--e and [Figure A1](#ijms-19-00693-f0A1){ref-type="fig"}b,c). This association was stronger in cancer samples than in normal breast tissues in all datasets for which normal tissues were available. Similar to ER$\alpha$, total PR protein was well correlated with *PGR* mRNA (Pearson' rho = 0.8593 and Spearman's rho = 0.8723).

Tumors positive for the HER2 receptor by histochemistry (TCGA dataset) did not express significantly different levels of Cx43 mRNA. However, when HER2 status was given by HER2 amplicon probes or HER2 mRNA expression (Vanvliet, NKI and Curtis datasets), HER2+ tumors had a significantly lower level of *GJA1*. No direct correlation was observed between *GJA1* and the HER2 (ERBB2) mRNA ([Figure 4](#ijms-19-00693-f004){ref-type="fig"}a--e and [Figure A4](#ijms-19-00693-f0A4){ref-type="fig"}a--d). A good correlation was observed between HER2 mRNA and total HER2 protein level (Pearson's rho = 0.8344, Spearman's rho 0.68634). The correlation between HER2 protein (HER2 and HER2_pY1248 activated form) and *GJA1* mRNA was not stronger than that observed for HER2 mRNA ([Figure 4](#ijms-19-00693-f004){ref-type="fig"}b--e and [Figure A3](#ijms-19-00693-f0A3){ref-type="fig"}d).

Together, the significant differences observed in *GJA1* mRNA level in individual subtypes and with receptor status suggest that *GJA1* level is dependent on the molecular context provided by such subtypes. In addition, *GJA1* does not vary directly with *ESR1* and HER2 mRNA and protein levels but shows a stronger correlation with *PGR* mRNA and PR protein in tumor samples.

2.5. *GJA1* mRNA Is Dysregulated at the Early Stages of Breast Cancer and Is Reduced with Grade When Tumors Are Pooled {#sec2dot5-ijms-19-00693}
----------------------------------------------------------------------------------------------------------------------

To reconcile evidence supporting both tumor-suppressive and -promoting roles, it has been suggested that Cx43 function could depend on tissue type or evolve with tumor stage \[[@B11-ijms-19-00693]\]. We therefore investigated whether *GJA1* expression in primary breast tumor changed with stage and grade at the mRNA level in breast cancer. Since grade/stage are strongly associated with subtype, we first stratified our cohorts by intrinsic subtype. We used the Curtis dataset, as *GJA1* expression was available for invasive tumors (stages 0 to IV) and "normal" adjacent tissue for numerous samples. A significant dysregulation of *GJA1* expression occurred at the early stages in all breast cancer subtypes, although both over-expression and downregulation could be observed ([Figure 5](#ijms-19-00693-f005){ref-type="fig"} and [Figure A5](#ijms-19-00693-f0A5){ref-type="fig"}). Most of the *GJA1* over-expressing luminal tumors were found to be of low stage (0--II). However, a reduction was observed in early stage basal-like and Her2e tumors ([Figure 5](#ijms-19-00693-f005){ref-type="fig"} and [Figure A5](#ijms-19-00693-f0A5){ref-type="fig"}). A significant increase in *GJA1* was also observed in the invasive stage I compared with stage 0 in all subtypes ([Figure 5](#ijms-19-00693-f005){ref-type="fig"}).

We then investigated whether or not the expression of *GJA1* could be linked to tumors' grade. Our analysis revealed that *GJA1* mRNA expression was significantly decreased with grade when all tumors were pooled, but not when they were stratified by intrinsic subtype ([Figure 6](#ijms-19-00693-f006){ref-type="fig"} and [Figure A6](#ijms-19-00693-f0A6){ref-type="fig"}). A significant decrease in *GJA1* with grades in LumB tumors could be observed only in the Vanvliet's dataset but not in other datasets analyzed ([Figure 6](#ijms-19-00693-f006){ref-type="fig"} and [Figure A6](#ijms-19-00693-f0A6){ref-type="fig"}).

Interestingly, basal and Her2e tumors, which express a low level of *GJA1* ([Figure 2](#ijms-19-00693-f002){ref-type="fig"}), account for an important proportion of grade 3 tumors, thus reducing the mean *GJA1* expression for this grade ([Figure 6](#ijms-19-00693-f006){ref-type="fig"}). Moreover, grade 1 tumors are mostly luminal A and B, with a subset of *GJA1* over-expressing tumors, introducing an upward bias in this grade. Grade 2 tumors consist of a more balanced mix of all the subtypes ([Figure 2](#ijms-19-00693-f002){ref-type="fig"} and [Figure 6](#ijms-19-00693-f006){ref-type="fig"}). These results suggest that an observed reduction in *GJA1* with grade in pooled tumors is likely a bias induced by the pooling of the tumors' subtypes.

2.6. In Her2e Breast Tumors, a Low Expression of *GJA1* Is Associated with a Better Prognosis {#sec2dot6-ijms-19-00693}
---------------------------------------------------------------------------------------------

To gain further insight into the role of Cx43 in breast cancer, we analyzed how the level of *GJA1* mRNA expression in each subtype was associated with outcome. Observations that Cx43 expression was associated with a worse prognostic in ER-negative \[[@B33-ijms-19-00693]\] and Her2e \[[@B34-ijms-19-00693]\] tumors have been previously reported using the web-based platform KMPlotter \[[@B35-ijms-19-00693]\] while ER-positive tumors had a better prognosis \[[@B33-ijms-19-00693]\]. Investigating further the results of BreastMark and KMPlotter Web platforms, survival analysis showed that pooled and luminal tumors with high levels of *GJA1* mRNA were associated with a better prognostic (hazard ratio \< 1), although results were not always statistically significant ([Figure 7](#ijms-19-00693-f007){ref-type="fig"} and [Figure A7](#ijms-19-00693-f0A7){ref-type="fig"}a,b). Conversely, basal-like and Her2e tumors followed an opposite trend (hazard ratio \> 1), with high expression of *GJA1* strongly associated with a worse prognosis in the Her2e subtype ([Figure 7](#ijms-19-00693-f007){ref-type="fig"} and [Figure A7](#ijms-19-00693-f0A7){ref-type="fig"}a,b).

Since the aggregation of several datasets in BreastMark and KMPlotter platforms could lead to artifacts in survival analysis, we went further by performing our own survival analysis for each subtypes for either aggregated ([Figure 7](#ijms-19-00693-f007){ref-type="fig"}) or individual datasets ([Figure A9](#ijms-19-00693-f0A9){ref-type="fig"} and [Figure A12](#ijms-19-00693-f0A12){ref-type="fig"}) following the determination of the best cutoff either by the receiver operating characteristic (ROC) curve ([Figure A8](#ijms-19-00693-f0A8){ref-type="fig"}a--c) or by the smallest *p* value of the log rank test for different thresholds (10--90) ([Figure A10](#ijms-19-00693-f0A10){ref-type="fig"}).

ROC curves have shown that the highest area Under the curve (AUC) for *GJA1* was obtained when tumors were pooled ([Figure A8](#ijms-19-00693-f0A8){ref-type="fig"}a) and *GJA1* was then ranked, at worst, in the eleven first percentiles when compared to all the probes present in the five datasets ([Figure A8](#ijms-19-00693-f0A8){ref-type="fig"}c). The log rank test was highly significant for all the analyses ([Figure 7](#ijms-19-00693-f007){ref-type="fig"}, [Figure A9](#ijms-19-00693-f0A9){ref-type="fig"} and [Figure A12](#ijms-19-00693-f0A12){ref-type="fig"}) and for a vast range of cutoffs ([Figure A10](#ijms-19-00693-f0A10){ref-type="fig"}c), suggesting that *GJA1* has the greatest discriminating power when cohorts are unstratified. This is in line with a differential expression of *GJA1* in luminal vs. basal and Her2e tumors that also have diverging prognostics ([Figure 2](#ijms-19-00693-f002){ref-type="fig"}a).

When analyzing individual subtypes, a high expression was also significantly associated with a better prognosis in all analyses for LumA and for most analyses for LumB tumors ([Figure 7](#ijms-19-00693-f007){ref-type="fig"}, [Figure A9](#ijms-19-00693-f0A9){ref-type="fig"} and [Figure A12](#ijms-19-00693-f0A12){ref-type="fig"}). However, survival curves in most analyses as well as the hazard ratio for a wide range of cutoffs ([Figure A11](#ijms-19-00693-f0A11){ref-type="fig"}) showed that this tendency is reversed in Basal and Her2e tumors where *GJA1* is mostly associated with a worse prognosis. This result was most significant in Her2e tumors, especially with smaller cutoffs while significance was rarely reached for Basal tumors.

However, *GJA1* ROC curves showed that *GJA1* did not consistently identify bad prognosis tumors with a high specificity and sensitivity ([Figure A8](#ijms-19-00693-f0A8){ref-type="fig"}a). These results suggest that although stratifying tumors revealed that the role of *GJA1* possibly differs in different breast cancer subtypes, *GJA1* should not be used as a clinical marker. These results also highlight once again how analyses using pooled tumor subtypes might induce biases and hide diverging results that are subtype-specific.

3. Discussion {#sec3-ijms-19-00693}
=============

Traditionally, Cx43 was considered as a tumor suppressor in the breast, with many studies reporting decreased Cx43 expression in tumor compared to normal breast tissue via both in vivo and in vitro studies \[[@B3-ijms-19-00693],[@B12-ijms-19-00693],[@B13-ijms-19-00693],[@B18-ijms-19-00693],[@B19-ijms-19-00693],[@B20-ijms-19-00693],[@B21-ijms-19-00693]\]. However, other studies contradict these findings \[[@B8-ijms-19-00693],[@B22-ijms-19-00693],[@B23-ijms-19-00693],[@B24-ijms-19-00693],[@B25-ijms-19-00693]\]. This recent evidence has cast doubt on Cxs tumor's suppressive role, suggesting that the Cxs function in cancer was tissue- and tumor stage-dependent \[[@B11-ijms-19-00693],[@B17-ijms-19-00693]\]. At least four different subtypes of breast cancer have been identified, each having unique molecular profiles, responses to treatment and prognostics. Our evidence suggests that the role of Cx43 is dependent on subtype.

3.1. Cx43 Expression Is Dysregulated in Breast Cancer {#sec3dot1-ijms-19-00693}
-----------------------------------------------------

Early studies first showed a dramatic downregulation of *GJA1* at the mRNA and the protein level in breast cancer cell lines as well as in rat and human breast tumors \[[@B12-ijms-19-00693],[@B13-ijms-19-00693]\]. Conversely, other studies showed an increase in a subset of tumors \[[@B15-ijms-19-00693]\]. Most of these studies analyzed a limited number of samples and were conducted either prior to the intrinsic subtype classification of breast cancer or did not use such classification. Our results, with several large cohorts of breast cancer clinical samples, reconcile these contradictory data by demonstrating that the observed dysregulation can involve both he increased and decreased expression of the Cx43 protein and mRNA. These observations are consistent with more recent reports at the protein level \[[@B15-ijms-19-00693],[@B16-ijms-19-00693],[@B25-ijms-19-00693],[@B36-ijms-19-00693]\].

3.2. Dysregulation of Cx43 Is Linked to Hormonal Receptor Status and Tumor Subtype {#sec3dot2-ijms-19-00693}
----------------------------------------------------------------------------------

Our results showed that the expression of Cx43 in breast tumors was lower in basal and Her2e than in normal tissues and that Cx43 levels vary greatly within luminal subtypes. This subtype-dependent expression was also shown by more recent studies, the result of which also support a higher expression of Cx43 mRNA and protein in luminal tumors than in basal-like and Her2e subtypes \[[@B36-ijms-19-00693],[@B37-ijms-19-00693]\]. Because the intrinsic subtypes are characterized by, among others, hormonal receptor status, we wanted to evaluate whether a functional link could be captured in whole-tumor expression profiles between Cx43 and ER$\alpha$, PR or HER2. Whole-tumor expression has been used by others, both to assess the content of specific cell types in samples and to decipher functional links between genes \[[@B38-ijms-19-00693],[@B39-ijms-19-00693]\]. Using this method, we showed that *GJA1* mRNA increases in a subset of ER$\alpha$- and PR-positive tumors and in the luminal subtypes, which are largely ER$\alpha$- and PR-positive. These results were not surprising as much evidence supports a link between Cx43 and hormones in breast tissue \[[@B32-ijms-19-00693]\] and in other tissues \[[@B40-ijms-19-00693],[@B41-ijms-19-00693],[@B42-ijms-19-00693],[@B43-ijms-19-00693]\]. *GJA1* is also expressed at lower levels when HER2 status is positive and within the Her2e breast cancer subtype, except in the TCGA dataset. In an early study, it was reported that Cx43 gap junctions were dramatically reduced in breast tumors, and that this reduction was considered to occur regardless of ER$\alpha$, PR or HER2 status \[[@B12-ijms-19-00693]\]. More recent studies have reported that Cx43 protein expression correlated positively with PR and ER$\alpha$ status \[[@B44-ijms-19-00693],[@B45-ijms-19-00693]\] and negatively with HER2 protein expression \[[@B45-ijms-19-00693]\]. However, Conklin et al. reported that no correlation was observed between Cx43 and HER2 protein in tissue microarrays \[[@B44-ijms-19-00693]\].

Our results suggest a direct relationship between *GJA1* and PR expression in breast cancer samples. Our analysis shows that *GJA1* level correlates with PR mRNA and protein in several subtypes. These results suggest that either PR or *GJA1* levels are dependent on the relative amount of some cell types co-expressing both genes, or that a functional link exists in the regulation of these genes in the same cell type or via paracrine signaling. Accumulating evidence has shown that ER$\alpha$ and PR are expressed in cell populations that do not totally overlap. *GJA1* is usually associated with basal cells while PR is thought to be expressed mainly in hormone-responsive luminal cell \[[@B1-ijms-19-00693]\]. However, PR has been detected in some human breast basal cells, especially within immature lobules \[[@B1-ijms-19-00693]\], suggesting an expression in primitive basal progenitor cells. PR has been suggested to coordinate basal cell proliferation, either via paracrine or autocrine stimulation \[[@B1-ijms-19-00693]\]. It was also reported that the unliganded progesterone receptor isoform A (PRA) could activate Cx43 transcription by interacting with AP-1 heterodimers composed of FRA2 and JUND \[[@B42-ijms-19-00693]\]. More studies are needed to better understand Cx43 localization and regulation, as well as its potential link with hormones. This knowledge is essential to further understand mammary gland morphogenesis and how Cx43 and hormones are involved in breast cancer.

Several other questions remain unanswered regarding the link between *GJA1* and ER$\alpha$, PR and HER2. While the receptor's protein and mRNA levels were well correlated in our study, their functional status in the samples is unknown. Protein expression data for some phosphorylated forms of ER (ER$\alpha$\_pS118) and HER2 (HER2_pY1248) receptor were available. Beyond single phosphorylation, the activation of these receptors is mostly dependent on complex post-transcriptional processing which affects receptors' specific functions and gene transcription. As a result, prognostic significance of ER$\alpha$ has been shown to be phosphorylation site-specific \[[@B46-ijms-19-00693]\]. Therefore, it cannot be excluded that *GJA1* mRNA expression can be regulated by ER$\alpha$ or HER2 and that these links could not be captured by expression profiles from breast cancer samples. Regardless of the precise nature of the link between *GJA1* and hormone receptors, our results suggest that *GJA1* level is dependent on the overall molecular context provided by each breast cancer subtype and that this might relate to *PGR* level, at least in some subtypes.

3.3. Upregulation of Cx43 mRNA Is Not Driven by DNA Amplification in Breast Cancer {#sec3dot3-ijms-19-00693}
----------------------------------------------------------------------------------

Somatic DNA-level chromosomal aberrations are a defining characteristic of cancer and are common in breast carcinoma. Genomic loss and amplification cause decreases and increases in the transcription of genes in the region and often with concomitant effects of protein expression. We found that *GJA1* is rarely the target of such somatic events, and when it occurred it was often in Her2e and basal subtypes, consistent with the observation that these two subtypes generally have an increased amount of genomic instability in comparison to the luminal subtypes. Our results are also in accordance with previous studies that have shown that the region of human chromosome 6 where *GJA1* is located (6q22.31) has a relatively low level of amplification and deletions \[[@B47-ijms-19-00693]\]. Cx43 was rarely mutated in breast cancer samples. Together, these results suggest that *GJA1* dysregulation at the mRNA and protein levels involves a dysregulation of other factors impacting the transcription (epigenetics, transcription factors) or mRNA stability.

3.4. Cx43 mRNA Level Is Dysregulated at the Early Stages of Breast Cancer {#sec3dot4-ijms-19-00693}
-------------------------------------------------------------------------

It was previously reported that, in primary tumors, Cx43 protein expression correlated with clinical stages \[[@B45-ijms-19-00693]\]. Our analysis of microarray data from large cohorts of primary tumors suggested that Cx43 is decreased in a subset of tumors during early carcinogenesis (stage 0) and is re-expressed at higher levels in stage I tumors. While stage 0 of the luminal subtypes showed an increased variance of expression, those of basal-like and Her2e tumors had a significantly reduced expression compared to normal tissues. However, we could not observe a robust mRNA reduction, or increase, in later stages compared either to early tumor stages or to normal tissues.

A previous study investigated immunohistochemistry for Cx43 protein expression in ductal carcinoma in situ (DCIS), DCIS with microinvasion, DCIS with invasive ductal carcinoma (IDC) and IDC alone. In pooled tumors as well as in most subtypes, the lowest expression of Cx43 protein occurred neither in DCIS nor IDC alone but precisely in DCIS with microinvasion where only three out of thirty-seven cases (8%) were positive \[[@B36-ijms-19-00693]\]. On the other side, out of 193 invasive lesions, sixty-three (33%) expressed Cx43. When looking specifically at the Her2e subtype, Cx43 was not expressed in a lower number of DCIS with microinvasion as in other subtypes since Cx43 was rarely expressed. Cx43 was present in only one of twenty IDC samples while the remaining twenty-six samples of other groups (DCIS, DCIS with microinvasion and DCIS with IDC) were all negatives. Whether or not the stromal compartment was included in the analysis was not specified. These results are consistent with our observation that, in all subtypes, DCIS (typically stage 0) had a lower expression than invasive stage I tumors. Together, these result point to Cx43 dysregulation as an early event in tumorigenesis, similar to what has been observed in the early stages of cervix, endometrial and thyroid cancers \[[@B48-ijms-19-00693]\].

Moreover, it should be noted that while breast cancer stages are based on the size and the spreading of the disease in the tissue or to distant sites, the mRNA expression profiles we used only account for gene expression in whole primary tumors. Important morphologic information is therefore lost. During cancer progression, localized neoplastic cells acquire the capacity to invade surrounding tissues, and eventually reach the blood or lymphatic vasculature, allowing them to spread to other organs \[[@B49-ijms-19-00693]\]. Depending on the stage and their location within the tumor or the tissue, these tumor cell populations face different challenges depending on the processes accomplished and on the microenvironment surrounding them \[[@B49-ijms-19-00693]\]. Microarray data do not make it possible to either finely assess the expression of specific cells according to their specific localization in the tumor or to distinguish tumor gene expression from the stroma. A comprehensive study of events occurring early in carcinogenesis and accounting for the geographical localization within the tumors at primary or distant sites, and for the different cell populations in a subtype-dependent manner, is therefore the next logical step in further understanding Cx43's role in tumor progression.

3.5. The Apparent Grade-Dependent Decrease in Cx43 Is Linked to Its Low Expression in More Aggressive Subtypes {#sec3dot5-ijms-19-00693}
--------------------------------------------------------------------------------------------------------------

Tumor grade is a measure of the degree of abnormality of tumor cells and of dedifferentiation of cancer tissues compared to normal breast tissue. Our results showed that, when all tumors are pooled, the *GJA1* mRNA level seems to increase in grade 1 tumors compared to normal tissues and gradually decrease with increasing grade. However, stratifying the tumors by subtype showed that within an intrinsic subtype, the distribution of the tumors within each grade varies considerably. Indeed, luminal A and B tumors are more frequently of grade 1 or 2 and some of them over-express *GJA1* ([Figure 2](#ijms-19-00693-f002){ref-type="fig"}), while most basal and Her2e tumors, that express a low level of Cx43, are mostly of grade 3. As a result, *GJA1* mRNA is not lost with grade in individual subtypes. These results suggest that the observed correlation in pooled tumors is, in fact, a bias attributable to the pooling of the tumors, and reflects the high grade of basal and Her2e tumors. These results also highlight how pooling the different intrinsic subtypes, expressing varying degrees of *GJA1*, can introduce important biases in cohort analysis and will likely yield different results depending on the composition, in terms of the subtypes, of the cohorts studied.

3.6. High Expression of Cx43 Is Associated with a Good Prognostic in Luminal Subtypes, but with a Worse Prognostic in Her2e Tumors {#sec3dot6-ijms-19-00693}
----------------------------------------------------------------------------------------------------------------------------------

Our results showed that, consistent with its ascribed role as a tumor suppressor in breast cancer, Cx43 was expressed at lower levels in more aggressive basal and Her2e subtypes than in luminal subtypes. Survival analysis of pooled tumors therefore showed a better survival of tumors highly expressing Cx43. However, as with grade, pooling breast cancer subtypes to analyze the effect of *GJA1* on the outcome introduces biases. Tumors expressing low levels of *GJA1* are overrepresented in aggressive basal and Her2e tumors, likely dragging down the survival of the group expressing a low level of *GJA1*. Therefore, performing survival analysis on pooled tumors, a good prognosis patient is automatically segregated into the curve of tumors highly expressing *GJA1*, and vice versa.

Paradoxically, the prognostic associated with Cx43 expression diverged depending on the intrinsic subtype, with a good prognosis in luminal tumors and an opposite trend in Her2e tumors. A previous study using immunohistochemistry found no correlation between Cx43 protein level and patient outcome \[[@B44-ijms-19-00693]\]. However, similar to our results, more recent studies using expression array-based survival curves found that a high *GJA1* expression was associated with a better prognosis in ER$\alpha$-positive breast cancer tumors, while an opposite trend was observed in ER$\alpha$-negative tumors \[[@B33-ijms-19-00693]\] and Her2e tumors \[[@B34-ijms-19-00693]\]. The worse prognosis associated with *GJA1* in Her2e tumors suggests that *GJA1* function in breast cancer might not just be tissue- and stage-dependent, as suggested by others \[[@B11-ijms-19-00693],[@B17-ijms-19-00693]\], but might also be subtype-dependent.

Cx43 has been reported to be expressed both in epithelial and stromal cells types. The molecular landscape provided by different cell types and/or by different breast cancer subtypes might provide different context, possibly allowing Cx43 to assume different functions and leading to different outcomes. It could be hypothesized that such context may provide different sets of interacting partners for *GJA1*, and its expression might even be driven by a different set of transcriptional or epigenetic regulators. In addition, an important determinant of the capacity of Cx43 to assume its channel function is unarguably its proper membrane localization. From array based mRNA expression data, it is until now impossible to assess neither the cellular localization nor the functional status of Cx43. It is very likely that these important and relevant information would contribute to a more complete understanding of the functions of Cx43 in breast cancer. For instance, a recent study demonstrated that over-expressing Cx43 in two different HER2-positive breast cancer cell lines lead to a diverging ability to proliferate, migrate, form mammospheres and form tumors in mice. Tumorigenic characteristics of the cancer cells were enhanced when functional gap junction channels could not be formed upon Cx43 over-expression, but were reduced when membrane gap junctions plaques allowed cells to communicate \[[@B34-ijms-19-00693]\]. These aspects of Cx43 biology might explain its different roles according to subtypes but also possibly within subtypes and should therefore be addressed. Additional researches are required to better understand the context that allows Cx43 to suppress or promote carcinogenesis in different intrinsic subtypes.

4. Materials and Methods {#sec4-ijms-19-00693}
========================

4.1. Gene Expression {#sec4dot1-ijms-19-00693}
--------------------

We used 4K samples over different expression platforms. Vanvliet used Affymetrix Human Genome U133A (data processed with Robust Multi-Array Average (RMA)) \[[@B50-ijms-19-00693]\]. Curtis discovery and Curtis validation used the Illumina HT-12 v3 platform (expression given as a Log2 intensity level) \[[@B47-ijms-19-00693]\]. The Cancer Genome Atlas (TCGA) used a custom Agilent G4502A 244K array (expression given as Log2 Lowess normalized ratio) \[[@B51-ijms-19-00693]\]. NKI used a Hu25K Agilent platform (samples were hybridized against a pool of equal amount of RNA from each patient and gene expression is given as a log10 of intensity ratio) \[[@B52-ijms-19-00693]\]. Normalized signal per probe or probe set mRNA expression was downloaded for tumor samples for all five datasets. Breast cancer intrinsic subtype was assigned to each sample with the Pam50 molecular subtyping algorithm using the R genefu package \[[@B29-ijms-19-00693]\]. Survival for each case was determined as in \[[@B27-ijms-19-00693]\].

ER$\alpha$, PR and HER2 status provided in the original publication of the dataset was used. For TCGA, ER, PR and HER2 status was obtained by immunohistochemistry (IHC). For NKI, ER and PR status was determined by IHC and the sample was considered positive if at least 10% of the cells were positive. For Vanvliet, ER and PR status was determined with the Bioconductor package ROCR based on the expression of the probe 205225_at and validated with IHC when available. NKI and Vanvliet HER2 status was determined using the probes of the HER2 amplicon genes. For Curtis datasets, ER, PR and HER2 status was based on mRNA expression. In the TCGA dataset, the level of some proteins has been investigated with reverse phase protein assay (RPPA). Data were available for total ER$\alpha$, PR and HER2 as well as for the phosphorylated forms of ER$\alpha$ (pS118) and HER2 (pY1248) that are at least partially indicative of the activation status \[[@B46-ijms-19-00693],[@B53-ijms-19-00693]\]. *GJA1* protein level obtained by mass spectrometry for 105 TCGA samples was retrieved from the protein report found at the Clinical Proteomic Tumor Analysis Consortium (CPTAC) data portal \[[@B54-ijms-19-00693]\]. Levels are given as the log2 of the ratio of each sample with respect to a pooled reporter sample.

4.2. DNA Alteration {#sec4dot2-ijms-19-00693}
-------------------

Copy number alterations (CNAs) were measured in the TCGA dataset with Affymetrix 6.0 single nucleotide polymorphism (SNP) arrays and segmented using Circular Binary Segmentation (labeled here as Relative linear copy number values) \[[@B51-ijms-19-00693]\]. Data were further processed by TCGA using GISTIC 2.0 to assign the Putative copy number calls per gene (−2: Homozygous deletion, −1: Hemizygous deletion, 0: Neutral/no change, 1: Gain, 2: High level amplification) \[[@B51-ijms-19-00693]\]. Mutations were detected using whole-exome sequencing after controlling for germline and normal adjacent tissue mutations \[[@B51-ijms-19-00693]\]. Linear and called CNA data as well as mutation data for the TCGA dataset were retrieved using R via cBioportal \[[@B55-ijms-19-00693],[@B56-ijms-19-00693]\]. A total of 977 patients had data for mutations \[[@B51-ijms-19-00693]\].

4.3. Survival Analysis {#sec4dot3-ijms-19-00693}
----------------------

Survival data was available for all five datasets. The log-rank test was used to estimate significance and hazard ratios (95% CI) were computed via Cox regression using survival package \[[@B57-ijms-19-00693]\]. ROC curves were computed using the pROC package \[[@B58-ijms-19-00693]\]. Kaplan--Meier plots were used to visualize the data. The best cutoff to determine tumors expressing high or low levels of Cx43 was selected using either the ROC curves or based on the smallest *p* value of the log rank test computed for each threshold between 10 and 90. For aggregated datasets analysis, each cohort was first split into groups based on the selected threshold and datasets were pooled only after splitting.

In addition, survival analyses were computed using the BreastMark and KMPlotter web platforms that use several well-known dataset \[[@B35-ijms-19-00693],[@B59-ijms-19-00693]\]. BreastMark allows thresholds of 25, 50 and 75 percentile to be selected to split the different cohorts used before aggregating them. For each analysis, we selected the threshold giving the best results. Since less samples were available in KMPlotter for statistical computation, we only included analyses for which there were at least 100 samples to draw both high and low expression curves for each subtype.

4.4. Statistical Analysis {#sec4dot4-ijms-19-00693}
-------------------------

All statistical analyses were carried out with R version 3.4.3 \[[@B60-ijms-19-00693]\]. For two class comparisons, (cancer vs. normal tissues; positive vs. negative hormonal status) the Wilcoxon-Mann-Witney test was used. When more than two classes were compared, the Kruskall-Wallis test was used followed by the Dunn post-hoc test to assess the statistical significance for each pair of samples (to compare subtypes). For stages and grades, differential gene expression was assessed using Limma package \[[@B61-ijms-19-00693]\]. A Benjamini-Hochberg correction was applied to adjust the *p* values for multiple testing. Because each subtype had a different number of patients, when correlation tests were performed between the expression of *GJA1* and the expression of other genes, a non-parametric bootstrap procedure was used for each subtype to derive the mean correlation coefficient and a percent confidence interval.

5. Conclusions {#sec5-ijms-19-00693}
==============

Our study has clarified the expression pattern of *GJA1* mRNA in breast cancer and showed that *GJA1* expression, as well as its prognostic significance, is dependent on breast cancer subtype. We also highlighted important biases that are introduced in analyzing pooled tumors. These biases need to be taken into consideration when studying *GJA1*, but also numerous other genes that are known to be linked, for instance, to ER$\alpha$ expression. Breast cancers are heterogeneous and genetically diverse and the lack of recognition of this molecular heterogeneity might explain the conflicting results from the literature, not only for *GJA1*, but potentially for other tumor suppressors or oncogenes. Overall, these results clearly showed that the molecular context where Cx43 is expressed in general, and the tumor subtypes of breast cancer in particular, should be taken into account when investigating Cx43's role in carcinogenesis.
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![*GJA1* mRNA level in breast cancer clinical samples is dependent on breast cancer subtype in four datasets. *GJA1* mRNA level in tumors stratified by subtype in Vanvliet, NKI, Curtis Discovery and Curtis Validation datasets. In the legend, "Breast" indicates adjacent normal breast tissue. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001.](ijms-19-00693-g0A1){#ijms-19-00693-f0A1}

![*GJA1* mRNA level in breast cancer clinical samples is higher in ER-positive tumors in four datasets. (**a**) *GJA1* mRNA level in breast tumors stratified by estrogen receptor status determined as described in Material and Methods. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001. (**b**) Expression of *GJA1* vs. estrogen receptor alpha (*ESR1*) mRNA in each subtype and in normal breast tissue. (**c**) Bootstrapped correlations between *ESR1* and *GJA1* mRNA level either in pooled breast cancer tumors or in individual intrinsic subtypes and in normal breast tissue. Data from Vanvliet, NKI, Curtis Discovery and Curtis Validation datasets.](ijms-19-00693-g0A2){#ijms-19-00693-f0A2}

![*GJA1* mRNA level in breast cancer clinical samples increases with *PGR* expression in four datasets. (**a**) *GJA1* mRNA level in breast tumors stratified by PR status determined as described in Material and Methods. In the legend, ""Breast" indicates adjacent normal breast tissue. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001; NS Not statistically significant. (**b**) Expression of *GJA1* vs. progesterone receptor (PGR) mRNA in each subtype and in normal breast tissue. (**c**) Bootstrapped correlations between *PGR* and *GJA1* mRNA level either in pooled breast tumors or in individual breast cancer intrinsic subtypes. Data from Vanvliet, NKI, Curtis Discovery and Curtis Validation datasets.](ijms-19-00693-g0A3){#ijms-19-00693-f0A3}

![*GJA1* mRNA level in breast cancer clinical samples is lower in HER2-positive breast tumors in four datasets. (**a**) *GJA1* mRNA level in breast tumors stratified by HER2 status determined as described in Material and Methods. In the legend, "Breast" indicates adjacent normal breast tissue. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001. (**b**) Expression of *GJA1* vs. *ESR1* mRNA in each subtype and in normal breast tissue. (**c**) Bootstrapped correlations between *ERBB2* and *GJA1* mRNA level either in pooled breast cancer tumors or in individual intrinsic subtypes and in normal breast tissue. Data from Vanvliet, NKI, Curtis Discovery and Curtis validation datasets. (**d**) *GJA1* mRNA vs. pY1248 phosphorylated form of HER2 protein level determined by RPPA in breast tumors from the TCGA dataset.](ijms-19-00693-g0A4){#ijms-19-00693-f0A4}

![*GJA1* mRNA level is dysregulated in the early stages of breast cancer in clinical samples. *GJA1* mRNA level for each tumor stage either in pooled breast tumors or stratified by intrinsic subtype. Data from TCGA and Curtis Validation datasets. In the legend, "Breast" indicates adjacent normal breast tissue. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001.](ijms-19-00693-g0A5){#ijms-19-00693-f0A5}

![*GJA1* mRNA level is reduced with grade in breast cancer clinical samples but only in pooled tumors. *GJA1* mRNA level for each tumor grade, in Vanvliet, NKI and Curtis Validation datasets, either in pooled breast tumors or stratified by intrinsic subtype. In the legend, "Breast" indicates adjacent normal breast tissue. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001.](ijms-19-00693-g0A6){#ijms-19-00693-f0A6}

![*GJA1* is associated with different outcomes depending on the breast cancer subtype. (**a**) BreastMark's; and (**b**) KMPlotter's web interface were used to complete the survival analysis for *GJA1* expression. Disease-Free Survival (DFS), Distant Disease-Free survival (DDFS), Overall Survival (OS) and Combined Survival (Combined) are given either for pooled tumors or for individual breast cancer subtypes in Breast Mark (**a**). Relapse-Free Survival (RFS) and Distant Metastasis-Free survival are given for *GJA1* probe 201667_at in KMPlotter (**b**). The best cutoff was determined manually for BreastMark (25, 50 or 75 percentile) based on *p* value and logrank score and automatically for KMPlotter.](ijms-19-00693-g0A7){#ijms-19-00693-f0A7}

![(**a**) Determination of the best cutoff for *GJA1* using ROC curves in individual subtypes of breast cancer. ROC curves evaluating the sensitivity vs. the specificity of *GJA1* as a marker of prognostic (occurrence of events in five years after tumor removal) in pooled tumors and each individual subtype of breast cancer of five datasets (TCGA, NKI, Vanvliet and Curtis discovery and Curtis validation). AUC, Area under the curve. The best cutoff is given in blue and is used in a subsequent survival analysis in [Figure A9](#ijms-19-00693-f0A9){ref-type="fig"}. (**b**) Expression of *GJA1* in pooled tumors and individual subtypes in five datasets. The red lines indicate the cutoff as determined by the ROC curves. In the legend, "Breast" indicates adjacent normal breast tissue. X indicates tumors with subsequent recurrence events. (**c**) Rank of the *GJA1* probe in pooled tumors and each individual subtype for five datasets. Rank given in percentile of the area under the ROC curve compared to all the other probes.](ijms-19-00693-g0A8){#ijms-19-00693-f0A8}

![Survival analysis of *GJA1* in individual subtypes of breast cancer with cutoff selected according to the ROC curve. Kaplan--Meyer plots show survival curves for patients with breast tumors expressing either high (blue) or low (red) levels of *GJA1* mRNA in pooled tumors or in individual intrinsic subtypes. TCGA, NKI, Vanvliet and both Curtis datasets were used for the analysis. The best cutoff was determined from ROC curves as in [Figure A8](#ijms-19-00693-f0A8){ref-type="fig"}.](ijms-19-00693-g0A9){#ijms-19-00693-f0A9}

![Determination of the best cutoff for *GJA1* using the log rank test *p* value in individual subtypes of breast cancer. Graph of the *p* value of the log rank test to compare the survival of patients with Cx43 expressed at high or low levels according to varying thresholds (10--90 percentile). Horizontal red lines indicate 0.05 *p* value. Vertical red lines indicate the threshold with the lowest *p* value for the log rank test, used for subsequent survival analysis in [Figure 7](#ijms-19-00693-f007){ref-type="fig"} and [Figure A12](#ijms-19-00693-f0A12){ref-type="fig"}. Results given for pooled tumors or individual breast cancer subtypes in our five datasets (TCGA, NKI, Vanvliet and Curtis discovery and Curtis validation) as well as in aggregated datasets (Pooled datasets).](ijms-19-00693-g0A10){#ijms-19-00693-f0A10}

![Cox regression hazard ratio associated with *GJA1* for different thresholds. Graph of the Cox regression hazard ratio to compare the survival of patients with Cx43 expressed at high or low levels according to varying thresholds (10--90 percentile). Horizontal red lines indicate a neutral hazard ratio of 1. Vertical red lines indicate the threshold with the lowest log rank test *p* value as determined in [Figure A10](#ijms-19-00693-f0A10){ref-type="fig"}, used for subsequent survival analysis. Results given for pooled tumors or individual breast cancer subtypes in our five datasets (TCGA, NKI, Vanvliet and Curtis discovery and Curtis validation) as well as in aggregated datasets (Pooled datasets).](ijms-19-00693-g0A11){#ijms-19-00693-f0A11}

![Survival analysis of *GJA1* in individual subtypes of breast cancer with the cutoff selected according to the log rank test *p* value. The Kaplan--Meyer plot shows survival curves for patients with breast tumors expressing either high (blue) or low (red) levels of *GJA1* mRNA in pooled tumors or in individual intrinsic subtypes. TCGA, NKI, Vanvliet and both Curtis datasets were used separately for the analysis. The best cutoff was determined as the percentile lending the lowest log rank test *p* value as in [Figure A10](#ijms-19-00693-f0A10){ref-type="fig"}.](ijms-19-00693-g0A12){#ijms-19-00693-f0A12}

![(**a**--**h**) The Human Protein Atlas normal and breast cancer tissue staining by immunohistochemistry for Connexin 43 (Cx43) (CAB010753 antibody). (**a**) Normal breast. Insert: Arrow head: myoepithelial cell's staining; arrow: luminal cell's staining. (**b--h**) Breast cancer tissue, (**h**) arrow: staining of spindle shaped stromal cells. Scale bar = 100 $\mathsf{\mu}$m. (**i**) *GJA1* mRNA expression in breast tumor vs. adjacent normal breast tissue in the The Cancer Genome Atlas (TCGA) dataset. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001. (**j**) Scatter plot showing Cx43 protein and *GJA1* mRNA level in tumors. In the legend, "Breast" indicates adjacent normal breast tissue. Pearson's correlation coefficient is given (r).](ijms-19-00693-g001){#ijms-19-00693-f001}

![The *GJA1* expression level is more variable in breast tumor than in normal tissue and varies with subtype. (**a**) The *GJA1* mRNA level in normal breast tissue and in each tumor intrinsic subtype. (**b**) The Cx43 protein level in each intrinsic subtype. In the legend, "Breast" indicates adjacent normal breast tissue. All data are from the TCGA dataset. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001; NS Not statistically significant.](ijms-19-00693-g002){#ijms-19-00693-f002}

![Somatic DNA-level events of *GJA1* do not drive expression changes of *GJA1* in breast cancer. (**a**) Percentage of tumors with a relative linear copy number \>1 (amplification, in red) and \<−1 (hemi- or homozygous deletion, in blue) for *GJA1* compared to other genes known to be altered in breast cancer. (**b**) Relative linear copy number value for each breast cancer subtype. (**c**) Somatic copy number alteration and putative copy number calls against mRNA expression for *GJA1* and *HSF2*. Copy number calls were computed by TCGA using GISTIC 2.0 (−2, Homozygous deletion; −1, Hemizygous deletion; 0, Neutral/no change; 1, Gain; 2, High level amplification). Pearson's correlation coefficient between relative linear copy number value and mRNA expression is given *GJA1* and *HSF2*. In the legend, "Breast" indicates adjacent normal breast tissue. (**d**) Contingency table and barplot showing the distribution of copy number alteration (CNA) by subtype. Due to the small number of samples in −2 and 2 CNA, Fisher's exact test was applied on −1, 0 and 1 CNA. (**e**) Total number and *GJA1* mutations observed in the 3 cases out of 988 patients. All data from the TCGA dataset. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001; NS Not statistically significant.](ijms-19-00693-g003){#ijms-19-00693-f003}

![Depending on the receptor status, *GJA1* is associated with different mRNA levels in clinical samples. (**a**) Expression of *GJA1* mRNA stratified by estrogen receptor alpha (ER$\alpha$), progesterone receptor (PR) and erb-b2 receptor tyrosine kinase 2 (ERBB2/Her2) status in the TCGA dataset. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001; NS Not statistically significant. (**b**) Plot of *GJA1* vs. *ESR1*, *PGR* and *ERBB2* mRNA (microarray) level in each subtype and in normal breast tissue. In the legend, "Breast" indicates adjacent normal breast tissue. (**c**) Bootstrapped correlations between *ESR1*, *PGR* or *ERBB2* and *GJA1* mRNA level either in pooled breast cancer tumors or in individual breast cancer intrinsic subtypes and in normal breast tissue. (**d**) Plot of *GJA1* mRNA vs. ER-alpha, ER-alpha pS118, PR or HER2 protein level assessed by reverse phase protein assay (RPPA). (**e**) Bootstrapped correlations between *GJA1* mRNA and ER-alpha, ER-alpha pS118, PR or HER2 protein level (RPPA). All data are from TCGA's BRCA dataset.](ijms-19-00693-g004){#ijms-19-00693-f004}

![*GJA1* mRNA level is dysregulated in clinical samples at the early stages of breast cancer. *GJA1* mRNA level for each tumor stage and for normal breast in the Curtis Discovery dataset, either in pooled breast tumors or stratified by intrinsic subtype. In the legend, "Breast" indicates adjacent normal breast tissue. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001.](ijms-19-00693-g005){#ijms-19-00693-f005}

![*GJA1* mRNA level is downregulated with grade in clinical samples only in pooled tumors but not in individual subtypes. *GJA1* mRNA level for each tumor grade in the Curtis Discovery dataset, either in pooled breast tumors or stratified by intrinsic subtype. In the legend, "Breast" indicates adjacent normal breast tissue. *p* value: \* \<0.05; \*\* \<0.01; \*\*\* \<0.001.](ijms-19-00693-g006){#ijms-19-00693-f006}

![*GJA1* is associated with a diverging outcome depending on breast cancer subtype. The Kaplan--Meyer plots show survival curves for patients with breast tumors expressing either high (blue) or low (red) levels of *GJA1* mRNA in pooled tumors or in individual intrinsic subtypes. TCGA, NKI, Vanvliet and both Curtis datasets were aggregated for the analysis. The best cutoff was determined as the percentile lending the lowest log rank test *p* value ([Figure A12](#ijms-19-00693-f0A12){ref-type="fig"}) and was 53 in Pooled tumors, 35 in luminal A (LumA) tumors, 68 in luminal B (LumB), 13 in Basal and 18 in Her2e tumors.](ijms-19-00693-g007){#ijms-19-00693-f007}
